Sorafenib Should Be Used With Caution in Dialysis Patients With Renal Cell Carcinoma

Share this content:
Sorafenib should be used “with caution” in metastatic renal cell carcinoma patients who are receiving hemodialysis treatments.
Sorafenib should be used “with caution” in metastatic renal cell carcinoma patients who are receiving hemodialysis treatments.

Sorafenib should be used “with caution” in patients with metastatic renal cell carcinoma (mRCC) who are receiving hemodialysis treatments, according to a systematic review of literature.1 The study is the first to investigate this issue, according to the authors.

Sorafenib is a multi-kinase inhibitor that is effective in terms of response rate and progression-free survival (PFS) for patients with mRCC who have previously received 1 systemic therapy, although most guidelines do not currently recommend it as a first-line therapy.

“The lack and heterogeneity of data regarding use of sorafenib in hemodialysis patients affected by mRCC encouraged us to review literature about this topic,” Alessandro Leonetti, MD, of the University Hospital of Parma, Italy, wrote in an email to Cancer Therapy Advisor. “No systematic review has been performed until now, and data are limited to few case reports and single center experiences.”

“Patients affected by mRCC undergoing hemodialysis are often not included in clinical trials because of their altered pharmacokinetics and comorbidities,” said Dr Leonetti. “More prospective studies, including this special population, are needed to give better clinical guidance.”

RELATED: Proteinuria Predicts for Renal Functional Decline in Patients With Kidney Cancer

Dr Leonetti and his colleagues evaluated literature about mRCC dialysis patients receiving sorafenib from January 1946 to August 2015. A total of 11 articles were included; 36 patients. The outcomes the researchers investigated were pharmacokinetics, toxicity, response rate, PFS, and overall survival (OS).

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs